{"title": "FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs", "author": null, "url": "https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2017/fda-removes-risk-evaluation-management-strategies-rems-for-esas", "hostname": "hematology.org", "description": "FDA Removes Risk Evaluation Management Strategies REMS for ESAs", "sitename": "Hematology.org", "date": "2017-04-13", "cleaned_text": "FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs Apr 13 2017 The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy. "}